RXRX vs SRPT: Which Stock Is the Better Buy?
Recursion Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — RXRX vs SRPT, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Recursion Pharmaceuticals, Inc. (RXRX) | Sarepta Therapeutics, Inc. (SRPT) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $74.26M | $2.20B |
| Net income (latest FY) | $-644.76M | $-713.41M |
| Revenue growth (5y CAGR) | 79.7% | 32.4% |
| Net margin | -868.3% | -32.5% |
| Return on equity | -57.0% | -62.5% |
| P/E ratio | — | 43.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full RXRX vs SRPT breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open RXRX's full financials → Open SRPT's full financials →More comparisons
Frequently asked questions
Which is bigger, RXRX or SRPT?
Recursion Pharmaceuticals, Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, RXRX or SRPT?
Over the last five fiscal years, Recursion Pharmaceuticals, Inc. grew revenue faster — 79.7%/yr versus 32.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
RXRX fundamentals → · SRPT fundamentals → · All 1,500+ companies → · Free screener →